Growth Hormone Deficiency (GHD) - Opportunity Assessment and Forecast

Growth hormone deficiency (GHD) is a rare disorder characterized by inadequate secretion of growth hormone (GH) from the anterior pituitary gland, a small gland located at the base of the brain that is responsible for the production of several hormones. GHD can be congenital (attributable to genetic mutations or structural defects in the brain), acquired (for example, resulting from trauma, infection, or tumor growth within the brain), or idiopathic (of unknown cause). Initial presentation may occur during childhood or adulthood.

Ascendis Pharma’s TransCon hGH (lonapegsomatropin) and Pfizer and OPKO Biologic’s Somatrogon, are the are the only late-stage treatment modalities in the GHD pipeline. There is one further therapy in Phase II, Hanmi Pharmaceuticals’ Efpegsomatropin, which is a GH receptor agonist with orphan drug designation in the EU. There is a critical need for improved diagnostic criteria across the GHD market and improved disease awareness across healthcare systems. Additionally, the launch of oral therapy LUM-21, in pipeline for a range of hormonal disorders, will drive market for oral therapies as they often lead to improved compliance.

Key Highlights

• During the 10-year forecast period, there is one major pipeline product on track to launch, driving a forecast growth in the 3MM from1.08BN in 2020 to1.57BN in 2030
• The long-acting GHs are anticipated to be priced at a small premium to the short-acting GHs due to their superior dosing regimens. Uptake of these drugs is expected to improve treatment rates and treatment adherence
• The launch of LUM-201 has the potential to increase treatment rates and treatment adherence among PEM-positive pediatric patients due to the more favorable oral administration route
• However, The GHD market is highly regulated in order to prevent GH misuse, examples of which include administering GH in order to improve athletic performance, induce anti-aging effects, or promote growth in healthy unaffected children. While these restrictions are often necessary, the stringent regulations may sometimes hinder the ability of those with legitimate GH requirements to access therapies in a timely manner

Key Questions Answered

• How will the Growth Hormone Deficiency market landscape in the 3MM (US, German and Japan) change from 2020-2030
• What are the most promising late-stage pipeline products for Growth Hormone Deficiency
• How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing treatment options
• What are the remaining unmet needs in Growth Hormone Deficiency
• What drivers and barriers will affect Growth Hormone Deficiency treatment sales in the 3MM over the forecast period

Scope

• Overview of Growth Hormone Deficiency , including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies
• Topline Growth Hormone Deficiency market revenue from 2020-2030. Annual cost of treatment and major pipeline product sales in this forecast period are included
• Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting Growth Hormone Deficiency treatment sales in the 3MM
• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products
• Analysis of the current and future market competition in the global Growth Hormone Deficiency market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to Buy this Report

The report will enable you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
• Develop business strategies by understanding the trends shaping and driving the global Growth Hormone Deficiency market
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the retinitis pigmentosa market in the future
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.